Gur Roshwalb
Managing Director @ aMoon Fund
Gur Roshwalb is a Series A investor at aMoon Fund focused on Biotechnology and Medical. Gur Roshwalb, MD, MBA, is a managing director at aMoon with over 15 years of healthcare industry and finance experience. Prior to joining aMoon, he was CEO at several private and public biotech companies. Before moving to industry, Gur was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in bothprivate and public companies. Gur started his finance career at Piper Jaffray, where he worked as a vice president and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, Gur was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he served as Chief Resident. Gur obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business and a B.A. from Columbia University.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Gur Roshwalb invests in
Stages Gur Roshwalb invests in
Countries Gur Roshwalb invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (100%)
- Medical 2 (50%)
- Health Care 2 (50%)
- Life Science 2 (50%)
- Pharmaceutical 2 (50%)
Stage
- Series A 2 (50%)
- Venture - Series Unknown 2 (50%)
Country
- United States 2 (50%)
- Israel 1 (25%)
- United Kingdom 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M / Venture - Series Unknown / Jun 16, 2021 | ||
| Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology.Samumed adopted a fresh operating philosophy from thebeginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health. | $120M / Venture - Series Unknown / Apr 15, 2021 | ||
| AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases.AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment ofcancer and immune-related inflammatory diseases.With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discovery and development of novel therapeutics for unmet medical needs.Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics.Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages. | $63M / Series A / Apr 15, 2021 | ||
| MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms. Its technology helps transform the therapy landscape of cancer and other severe diseases that enable doctors and physicians to cure diseases and develop medicines that restore normal function to patients' cells.The company was founded in 2008 and is headquartered in London, England. | $29.5M / Series A / Sep 10, 2020 |
Co-Investors
About aMoon Fund
aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science toaccelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.
aMoon Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Moshe Mor
General Partner
|
|||
|
Gur Roshwalb
Managing Director
|
|||
Itay Bengad
Executive in Residence
|
|||
Marius Nacht
Founder & Anchor Investor
|
|||
Michal Goren Miller
Chief Legal Counsel & Chief Compliance Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Gur Roshwalb invest in?
Gur Roshwalb invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gur Roshwalb?
Public channels for Gur Roshwalb include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gur Roshwalb last invest?
The most recent investment recorded for Gur Roshwalb closed in Jun 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
